October 24, 2012
Astellas Pharma announced on October 23 that the company has launched its overactive bladder (OAB) treatment Myrbetriq (brand name in the US; mirabegron) in the US. Myrbetriq is a selective β 3 adrenergic receptor agonist discovered by Astellas. The drug...read more